Rigontec scores additional €15M in extended Series A
September 07, 2016
Biotechnology | Bonn, Germany | Series A
Rigontec has announced a third and final close of its Series A on €29.25 million. The company is a provider of RNA therapeutics with applications in both immediate and long-term anti-tumor immunity and the treatment of infectious and inflammatory diseases.